Objective: To study the influence of type of inhalation device on medication adherence of COPD patients. Methods: Adherence to inhalation medication of 795 patients was recorded from pharmacy records over 3 years. It was expressed as percentage and deemed good at ≥75-≤125%, suboptimal ≥50-<75%, and poor <50% (underuse) or >125% (overuse). Since most patients used more than one device, 1379 medication periods were analyzed. Results: Patients using a Metered Dose Inhaler (MDI) or Diskus had a 2.3-fold and 2.2-fold increased risk, respectively, of suboptimal adherence versus good adherence, compared to Handihaler and a 2.1-fold and 2.2-fold increased risk, respectively, of underuse versus good adherence compared to Handihaler. Turbuhaler, MDI, Respimat had a 7.9-fold, 3.5-fold, and 2.0-fold increased risk, of overuse versus good adherence compared to Handihaler. Conclusions: In COPD, adherence to inhalation medication is device-related. Overuse was most pronounced for devices without a dose counter, devices with the ability to load a dosage without actual inhalation, or devices lacking feedback of correct inhalation. The design of the device seems to be related to underuse and overuse of inhaled medication. Future research might investigate whether prescribing a different device with similar medication improves therapy adherence.
Introduction
In the treatment of Chronic Obstructive Pulmonary Disease (COPD), therapy adherence is an important issue. Therapy adherence to medication in COPD has an extra dimension compared to, for example, the treatment of cardiovascular disease, because most medications are inhaled. In order to inhale medication a patient has to use an inhalation device properly for an effective drug delivery to the lung. The cognitive function, dexterity, and inhalation strength of a patient have to be adequate to be able to use such an inhalation device successfully. [1] Poor drug efficacy can be caused by a decreased medication delivery associated with incorrect inhaler technique for the device being used.
The design of the inhaler plays a significant role in the effectiveness of inhaler therapy, with up to 94% of the patients using their inhaler ineffectively. [2] For example the effectiveness of a powdered drug to inhale mainly depends on the inspiratory flow rate generated by the patient and on the intrinsic resistance of the DPI device. These two forces affect the dose utilization, both the powder disaggregation and dispersion, its penetration into the airways, and finally the efficacy of the treatment. [3] The effectiveness of inhaled medications is also strongly influenced by the patient's medication adherence, which has been shown to be associated with reduced risk of death and hospitalizations due to exacerbations in COPD. [4, 5] Medication adherence can be influenced by patientand medication-related factors. Patient-related factors are disease and treatment acceptance, knowledge about and faith in the treatment, effective patient-clinician relationships, and routinization of drug therapy. [6] [7] [8] Medication-related factors known to have a negative influence on adherence are frequent daily use and multiple dosing. [9] COPD patients often have a medication regimen that requires multiple daily dosages over a prolonged period of time and they often use various medications simultaneously. All these factors together can make therapy adherence for COPD patients a difficult task. In COPD and asthma the level of patient satisfaction with their inhaler device is observed to have a positive influence on the treatment goals by improved compliance. [10, 11] In a study of Chrystyn et al. it was shown that the principal inhaler attributes influencing overall patient satisfaction were whether it was built to last and would not break easily, whether it was easy to hold and carry, and whether the instructions were simple and easy to follow. [11] Feedback to indicate correct inhalation is a feature patients also find important. [12] Rau et al. stated, based on a summary of studies, the top three features an ideal inhaler should possess including: ease of use during an exacerbation, knowing how many dosages are left, and overall ease of use. [13] We therefore conducted a study to investigate the relationship between therapy adherence and the devices in which inhalation medication for COPD is administered.
Methods

Setting and design
This study is part of the Cohort on Mortality and Inflammation in COPD (COMIC), a single-center prospective cohort study. From December 2005 to April 2010, 795 patients were included with a follow-up period of 3 years. Patients were recruited at the outpatient clinic of the Department of Pulmonology, Medisch Spectrum Twente Hospital, Enschede, located in the Eastern part of The Netherlands, serving a catchment population of approximately 264,000 persons. The study was approved by the hospital's Medical Ethical Committee. All patients provided written informed consent. [14, 15] To be eligible for the study patients had to have a clinical diagnosis of COPD, as defined by the GOLD criteria. Patients were consecutively enrolled when hospitalized for an acute exacerbation of COPD or when visiting the outpatient clinic in stable state. All surviving patients completed the 3-year follow-up period and were treated according to standard care. Demographic data was collected from medical records. Lung function and smoking status were both determined at baseline. Lung function was measured by spirometry, performed according to standardized guidelines. [16] Smoking status was determined by the Vlagtwedde questionnaire. [17] The primary outcome, therapy adherence, was recorded from patients' pharmacy records. The patients were a priori not aware that their medication records were going to be used for the monitoring of therapy adherence. Theoretical duration of medication use was calculated using information on dispensing date, total supply, and dosage regimen. We computed the total number of days for which patients had collected medication during follow-up and divided this by the total number of days between the first and last medication collection during follow-up (36 months) plus the days belonging to the last refill. The total follow-up could therefore be prolonged with the days of the last refill. [18] This was expressed as a percentage. Adherence was deemed good if it was ≥75-≤125%, suboptimal between ≥50-<75%, and poor below 50% (underuse) or above 125% (overuse). In the literature there is no consensus on acceptable therapy adherence, with definitions varying from >70% to >80% in clinical research settings. We decided to set the limit for optimal adherence at ≥75%, which is between these two definitions. Next to this, we decided to choose an upper cutoff point as well for good adherence (at 125%), in order to exclude overuse from this category. [4, [19] [20] [21] We excluded medication when it was prescribed once only or was used for less than 90 days. Seven devices were considered in the study: Metered Dose Inhaler (MDI), Autohaler, Respimat and the dry powder inhalers Handihaler, Diskus, Cyclohaler, and Turbuhaler.
The devices used in this study were prescribed by the physicians. With the current data we have no information on whether each physician has taken the preference of the patient into account.
Therapy adherence with short-acting beta 2-and muscarinic agonists, and formoterol were not analyzed because these medications (unlike salmeterol) can be used on demand as well and this confounds the calculation of adherence. [22] Because most patients in the COMIC study were either on combined ICS preparations or on single ICS preparations combined with either long-acting anticholinergic or long-acting beta2-agonists, as is recommended for the treatment of COPD, many patients used more than one type of inhaled medication. Since use of one medication in different devices (e.g. MDI and Diskus) was scored separately during the observation period, data on 1379 periods of medication use are presented.
Statistical analyses
Baseline characteristics are reported as mean with SD for continuous variables, or as numbers with corresponding percentages for nominal variables. Not normally distributed continuous variables are reported as median with the corresponding interquartile range (IQR).
We investigated the relationship between type of device and therapy adherence with Nominal Regression analyses. Furthermore, potential confounders (age, sex, smoking status, lung function) were first tested for their association with therapy adherence. Variables associated with adherence were subsequently tested for their association with type of device. For categorical variables this association was tested by means of Chi-square tests or Fisher exact tests, as appropriate. For continuous variables this association was tested with an ANOVA or Kruskall Wallis test as appropriate. Variables that were both associated with therapy adherence and type of device were all entered in the multivariate Nominal Regression analyses. Subsequently, potentially confounding variables with the highest p-value were eliminated from the model one by one until the fit of the model decreased significantly, based on the −2 Log Likelihood.
Since not all inhaled drug substances COPD patients use are available in every device, adherence to the type of the device is in some instances identical to adherence with the inhalation medication delivered by this device. It is therefore not possible to study adherence with an inhalation device without the interference of the inhalation medication delivered by the device. Also, because of the strong association between device and medication a statistical correction for the inhaled medication is not feasible because of the phenomenon of multicolinearity.
To compare the four categories of therapy adherence between inhalation devices we used multivariate Nominal Regression analyses. Good adherence was set as reference. Because the highest percentage of patients with good adherence was observed for Handihaler, this device was set as reference in Table 1 . We excluded Autohaler and Cyclohaler from these analyses because numbers were too small to obtain reliable estimates. Furthermore, of the potential confounders listed in Table 2 , FEV 1 in liters, FEV 1 % predicted and FEV 1 /VC ratio were all associated with type of device as well as with therapy adherence and were therefore potential confounders that should be entered to the multivariate Nominal Regression analyses. Due to multicolinearity between these three lung function parameters, only the variable with the best model fit was entered to multivariate Nominal Regression analyses, which was FEV 1 in liters.
All statistical calculations were carried out with SPSS version 21.0. P-values <0.05 were considered significant.
Results
The study population included 795 patients (Table 2) . Patients, mean age 68 years, were predominantly male (61.1%). Almost three-quarter of the patients were exsmokers.
The devices most used were Handihaler (used for tiotropium) and MDI (used for salmeterol/fluticasone (78.2%), fluticasone (6.2%), ciclesonide (5.4%), salmeterol (4.2%), beclomethasone dipropionate extra fine (2.7%), budesonide (2.0%), and beclomethasone (1.2%)). (Table 3) We investigated therapy adherence for the different types of inhalers. The results are listed in Table 4 . The percentages of patients with good therapy adherence within the studied devices ranged from 38.5 (Cyclohaler) to 77.6% (Handihaler). Suboptimal adherence ranged from 6.7 (Autohaler) to 38.5% (Cyclohaler), For overuse MDI and Turbuhaler differed significantly from the Handihaler. MDI showed a 3.5 times higher risk while the Turbuhaler showed a 7.9 times higher risk of overuse compared to the Handihaler with optimal therapy adherence.
Next to this MDI differed significantly from Diskus with a 2.1 times increased risk of overuse compared to Diskus with optimal adherence.
Turbuhaler showed a 3.9 times increased risk of overuse compared to Respimat and a 2.2 times increased risk of overuse compared to MDI and a 4.7 times increased risk of overuse compared to Diskus with optimal use. FEV 1 at baseline was related to poor adherence, both underuse and overuse. Underuse was associated with a higher FEV 1 at baseline compared to good adherence, while overuse was associated with a lower FEV 1 at baseline compared to good adherence.
Discussion
Therapy adherence to inhalation medication for the treatment of COPD is related to the device in which the medication is administered.
The highest percentage of optimal therapy adherence was found for the Handihaler (78%). Overuse was found most often for the MDI (14%) and Turbuhaler (27%).
Overuse can be due to both spillage and overdosing. With the Turbuhaler spillage could be caused by the design of the Turbuhaler, since it enables patients to load the device several times by rotating the grip, without actually inhaling. The ability of a device to indicate the release of a dosage without actually inhaling therefore increases the risk of overuse as registered in pharmacy records. Next to this, when a device does not provide feedback on actually inhaling, a patient can feel the need to load a dose and/or inhale again to be sure about taking a dose, which results in overdosing. For example the medication in the Turbuhaler has no taste. This can make a patient insecure about whether they have actually taken the medication. The majority of the Turbuhaler records in our cohort contain budesonide/formoterol (72%). In asthma maintenance therapy this combination can be used on demand (SMART regimen) when a patient experiences an increase in symptoms due to the short onset of symptom relieve of formoterol. [23] It is possible that this therapy advice is used off-label for the treatment of COPD as well, and because of the high prevalence of symptoms in patients with COPD, this might lead to overuse.
For MDIs, overuse might in part be caused by for example 'test-puffs' to see whether the device still contains medication. Most MDIs lack a registration of dosages left in the device. Maybe patients discard their MDI too early because they do not know how many dosages are left. This is in line with LaForce et al. who showed that a dose counter relieves anxiety about running out of medication. [24] In the COMIC study population most MDI prescriptions were for the salmeterol/fluticasone combination (78%). This MDI has a counter to register the dosages left in the device. The Respimat has a marker when a patient starts with the last 10 dosages. The Turbuhaler has a marker that becomes red when there are approximately 20 dosages left, the least precise indicator of these three inhalers.
Despite the counters mentioned above we see overuse happening.
The fact that MDIs are difficult to handle and require critical hand-lung coordination, when not combined with a spacer device, can be a cause of overuse. Many studies have shown that numerous patients with MDIs make critical inhalation errors that result in reduced delivery of the medication into the lungs. When this is experienced as reduced efficacy, patients might use their inhaler again. The use of a spacer improves drug availability. [25] It is possible that patients showed overuse because they did not use a spacer and therefore experienced reduced efficacy. Although it is common practice in the studied population to prescribe an MDI combined with a spacer including patient instruction, the use of a spacer combined with an MDI could not be derived from our database.
The dry powder inhalers, including Diskus, Handihaler, and Turbuhaler, are flow-dependent devices and require minimal coordination. [26] They are also associated with lower rates of incorrect handling, when compared with the MDI device (without spacer). [24] Diskus and MDI have a higher risk of underuse compared to Handihaler. With an MDI a patient can still actuate the inhaler with little or no drug beyond the maximum number of dosages left in the canister. The pharmacy data show underuse while a patient may believe he is still using his medication properly. This is unlikely to happen with the Diskus once it is empty due to the dose counter. In contrast to the MDI, the Respimat cannot release a mist after the last dosage is delivered, which prevents patients from using an empty device.
The literature shows that there are aspects in the design of an inhaler that can influence a patient's satisfaction with an inhaler and therefore might influence therapy adherence. A patient's satisfaction with an inhaler is likely to be based on the efficacy of the inhaled medication as well. [10, 11] Previous analyses of the COMIC therapy adherence data showed that therapy adherence to inhalation medication for the treatment of COPD is related to the medication prescribed. The medication dosed once daily, tiotropium and ciclesonide, showed the highest adherence. The good results for Handihaler might therefore be influenced by the medication tiotropium. Therapy adherence seems to be influenced by dosage scheme and dosing once daily seems to improve therapy adherence. [27] Also, corticosteroids are not bronchodilators and do not give immediate relief of breathlessness, whereas tiotropium does relieve dyspnea, albeit with a relatively slow onset. [28] The medication inhaled with a Diskus is dosed two times per day and multiple dosing is known to decrease therapy adherence. Salmeterol, inhaled with Diskus, also has a slow onset of effect. To improve adherence numerous combinations of drugs in one inhaler were introduced. But the concept of improving adherence with the combination of drugs in one inhaler could not be supported with the COMIC data. [14] Unfortunately, not all inhaled drug substances COPD patients use are commercially available in every device, so it is not possible to study adherence without the interference of the inhalation medication delivered by the device. However, as can be seen in Table 3 , there are several medications that are delivered in multiple devices in which the design of a device can explain aspects of therapy adherence.
Next to the type of device, also FEV 1 at baseline was related to poor adherence, both underuse and overuse. Underuse was associated with a higher FEV 1 at baseline compared to good adherence, while overuse was associated with a lower FEV 1 at baseline compared to good adherence. It is possible that patients with higher FEV 1 show lower adherence levels because they feel less need to use their medication. The opposite can be an explanation for overuse in patients with a lower FEV 1 .
There are some potential limitations in our study. Pharmacy records show maximum levels of medication use in patients. There is no assurance the patient is actually inhaling his medication successfully. Also changes in dosage regimen advised by the prescriber without giving a new prescription are not reflected in the pharmacy data. It is plausible that the actual inhaled drug volumes are lower than the volumes dispensed through the pharmacy. [29, 30] Despite these limitations, this study has major advantages. The therapy adherence data reflect reallife use because of the observational design of the study. Computerized pharmacy data made it feasible to monitor medication adherence by tracking requests for refills. Computerized drug-dispensing histories from Dutch pharmacies are virtually complete and include data concerning the dispensed drug, the prescriber, the dispensing date, the amount dispensed, the prescribed dose regimens, and the estimated duration of use. In the Netherlands, there is a strong pharmacy-patient liaison for reimbursement of prescription drugs, a high degree of computerization, the use of standardized classification and coding systems, and a strong commitment of pharmacists to surveillance of medication.
Next to this, the possibility to link adherence to lung function, the reliable diagnosis of COPD (which studies with pharmacy data alone often lack), and the 3-year follow-up of medication use in COPD are of great benefit.
Conclusion
A striking result was the overuse with MDI and Turbuhaler, which are devices that have the ability to load a dosage without actual inhalation, or don't have a dose counter, or do not provide feedback of an inhalation. Further research is needed to investigate whether improving the design of an inhalation device (e.g. devices without the ability to load a device without actually inhaling, and devices providing a feedback on correct inhalation) leads to improved adherence.
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